Summit Therapeutics (SMMT) EBITDA Margin (2019 - 2022)
Summit Therapeutics (SMMT) reported EBITDA Margin of 9742.73% for Q3 2022, down 817955.0% on a YoY basis from N/an in Q3 2021, and down 43.26% quarter-over-quarter from 6800.85% in Q2 2022.
Summit Therapeutics (SMMT) EBITDA Margin (2019 - 2022) Analysis & Trends
Summit Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 9742.73% in Q3 2022.
- For the quarter ending Q3 2022, EBITDA Margin fell 817955.0% year-over-year to 9742.73%; the trailing twelve-month figure through Jun 2023 stood at 271352.27% (down 26717354.0% YoY), and the FY2022 full-year result was 11131.63%, down 632207.0% from the prior year.
- EBITDA Margin for Q3 2022 stood at 9742.73%, down from 6800.85% in the prior quarter.
- The five-year high for EBITDA Margin was 14869.23% in Q4 2019, with the low at 41887.72% in Q2 2021.
- Historically, EBITDA Margin has averaged 8075.57% across 4 years, with a median of 8517.68% in 2020.
- Annual changes were most pronounced in 2021 — EBITDA Margin tumbled 3286948 bps — and 2022, when it jumped 3508687 bps.
- Summit Therapeutics' EBITDA Margin stood at 14869.23% in 2019, then tumbled by 137 bps to 5524.86% in 2020, then plunged by 86 bps to 10300.4% in 2021, then climbed by 5 bps to 9742.73% in 2022.
- The last three EBITDA Margin figures came in at 9742.73% (Q3 2022), 6800.85% (Q2 2022), and 9262.8% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -9,742.73% |
| Jun 30, 2022 | -6,800.85% |
| Mar 31, 2022 | -9,262.80% |
| Dec 31, 2021 | -10,300.40% |
| Sep 30, 2021 | -1,563.18% |
| Jun 30, 2021 | -41,887.72% |
| Mar 31, 2021 | -8,756.77% |
| Dec 31, 2020 | -5,524.86% |
| Sep 30, 2020 | -8,517.68% |
| Jun 30, 2020 | -9,018.24% |
| Mar 31, 2020 | -3,320.37% |
| Dec 31, 2019 | 14,869.23% |
| Sep 30, 2019 | -5,156.08% |